Transradial access (TRA) for percutaneous coronary intervention (PCI) is associated with a reduced risk of mortality compared with transfemoral access, access site-related bleeding complications, and shorter length of stay. The budget impact from a healthcare system that has largely transitioned to TRA for PCI has not been previously published.
P
ercutaneous coronary intervention (PCI) is the most common form of revascularization in patients with coronary artery disease in both the elective and the emergency settings. Historically, the femoral artery has been the access site of choice. However, both randomized controlled trials and national registries with large unselected patient populations have shown that transradial access (TRA) is associated with a reduced risk of mortality compared with transfemoral access (TFA), as well as lower rates of access site-related bleeding complications and a shorter length of stay (LoS). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] TRA is, therefore, increasingly being adopted as the primary access site for PCI across the United States and many countries in Europe and Asia. 12 Despite the evidence and recommendations supporting TRA, there is a significant variation in its uptake both between and within countries. In the United Kingdom, TRA has become the dominant access site, representing 80.5% of procedures in 2015 with hospital adoption rates varying from 18% to over 95%. 13 In the United States, studies derived from the National Cardiovascular Data Registry have also demonstrated significant heterogeneity in adoption of TRA, varying from 12% in the Northeast to 38% in the South. 14 In addition to the clinical benefits of TRA, economic analyses in the United States and China have shown healthcare cost savings, primarily because of the lower rate of complications and shorter hospital stay for TRA, although these studies were limited as they were either derived from single centers or excluded patients with acute coronary syndromes where the benefit associated with TRA is arguably at its greatest. [14] [15] [16] [17] To the best of our knowledge, there has not been a previous national health economic analysis of access site practice in PCI, for an unselected all-comer population. Furthermore, no previous studies have considered a European perspective using real-world data, and no studies have examined the impact of the rate of adoption of TRA on national healthcare budgets.
We have, therefore, undertaken a health economic analysis to study differences in healthcare expenditure associated with access site practice in an unselected national cohort of patients undergoing PCI in England during a period of change in access site practice. The objectives of the current study were to estimate (1) the differences in procedure cost, LoS, complications, and cost of complications between TRA and TFA and (2) the additional costs that could have been saved if TRA uptake has been more uniform across the country.
METHODS
An economic model was developed to synthesize clinical outcomes and resource use (such as LoS and National Health Service [NHS] unit costs) for transradial and transfemoral PCI based on data from the British Cardiovascular Intervention Society (BCIS)-National Institute for Clinical Outcomes Research database. The overall approach was based on that of the UK National Clinical Guideline Centre cost analysis that was developed to inform National Institute of Clinical Excellence Clinical Guideline for the management of patients presenting with ST-segment-elevation myocardial infarction (STEMI). 18 To reflect differences in patient profiles, clinical outcomes, LoS, and costs, the economic model was developed for 3 indications: non-STEMI (NSTEMI), STEMI, and stable angina.
Clinical Data
BCIS collects data on all PCI procedures in the United Kingdom, with data collection coordinated by the National Institute of Cardiovascular Outcomes Research (http://www. ucl.ac.uk/nicor/) via the Central Cardiac Audit Database. In 2011, this data set collected information on 99.4% of all PCI procedures performed in NHS hospitals in England and Wales. The BCIS National Institute for Clinical Outcomes Research database contains a total of 113 variables, including information on clinical and procedural parameters, as well as patient outcomes. Data on English residents undergoing PCI in the NHS in the United Kingdom between 2010 and 2014 were provided from this database, aggregated by indication (elective/stable, NSTEMI/unstable angina, and STEMI), Strategic Health Authority (these were part of the structure of the NHS in England between 2002 and 2013 and were responsible for enacting the directives and implementing fiscal policy as dictated by the Department of Health at a regional level), and access site. 19 A small proportion of procedures (2.9%)
WHAT IS KNOWN
• Transradial access for percutaneous coronary intervention is associated with a reduced risk of mortality compared with transfemoral access, access site-related bleeding complications, and shorter length of stay.
• The budget impact from a healthcare system that has largely transitioned to transradial access for percutaneous coronary intervention has not been previously published.
WHAT THE STUDY ADDS
• Our analysis of the budget impact of transradial uptake in percutaneous coronary intervention from a national perspective finds that transradial access is 25% less costly on a per-procedure basis in England compared with transfemoral access.
• The cost saving associated with the current adoption rates for the transradial approach between 2010 and 2014 is £13.31 million; had all regions adopted the radial approach the total national cost savings would be £33.40 million.
• The main component of these savings is the reduction in hospital stay, and the highest risk acute cases (ST-segment-elevation myocardial infarction cases) had the greatest benefit associated with transradial access.
were classified as multiple/other, when the access site was not clear or >1 site was used in the same procedure; these data were excluded from this analysis. During PCI, it is possible that the primary point of access fails and that access has to be changed during the procedure (access site crossover). Access site crossover is not captured in the BCIS data, but was included in this analysis as a contributor to procedure costs with access site crossover rates that were obtained from the RadIal Vs. femorAL access for coronary intervention study 10 for STEMI and NSTEMI/unstable patients. As crossover rates could not be identified for stable patients from the literature, the pooled crossover rates for STEMI and NSTEMI/unstable patients from the RIVAL study were applied (Table I in the Data Supplement).
Complications that were included in the economic model were major bleeding and vascular complications for rate of event and cost and major adverse cardiac event (MACE) for rate of event only. MACE was defined as a composite of inhospital mortality, myocardial infarction, or repeat intervention. Arterial access site complication was defined as any pseudoaneurysm or any access site hemorrhage requiring intervention or delaying discharge. Bleeding was defined as any gastrointestinal bleed, intracerebral bleed, retroperitoneal bleed, or transfusion. 1 The 2010 to 2014 data for England as a whole were used for the base case analysis to compare the cost of transradial and transfemoral PCI.
Costs
A breakdown of the unit costs used in the economic model and an example flow diagram is provided in the Table II in the Data Supplement. Procedure and access site crossover costs differ between TRA and TFA, because of different equipment used for each procedural method. It should be noted that the procedure costs are not exhaustive, as they do not include the cost of consumables such as stents and balloons, or costs of using the catheterization laboratory, as these are likely to be similar for both approaches. However, the cost of a day's stay in hospital and the costs of treating major bleeding and vascular complications are assumed to be the same regardless of access site, and any differences between the 2 approaches are because of a different LoS and different rates of complications associated with each method. The cost per day of a hospital stay is taken from the NHS national schedule of reference costs for 2015 to 2016 20 and is calculated as a weighted average of all the PCI Healthcare Resource Groups (Table II in the Data Supplement).
The cost of major bleeding is assumed to be composed of a blood transfusion, calculated as the cost of a unit of red blood cells 21 multiplied by the average number of units used in a transfusion. 22 Although Clinical Guideline 94 included an extra 6 days in hospital for the management of NSTEMI and unstable angina, 23 it was considered that this time was already accounted for in the BCIS National Institute for Clinical Outcomes Research data set; this additional time was, therefore, not included in this model. The cost of vascular complications is assumed to include an ultrasound, a compression device, a thrombin injection, and vascular surgery. The costs of an ultrasound and vascular surgery are taken from the NHS national schedule of reference costs for 2015 to 2016, 20 and the cost of a compression device and a thrombin injection is assumed to be the midpoint of the ranges reported in the cost analysis from the National Clinical Guideline Centre for patients presenting with STEMI, 18 which are then inflated using Personal Social Services Research Unit inflation data. 24 The percentage utilization of an ultrasound, a compression device, a thrombin injection, and vascular surgery was taken from the cost analysis from the National Clinical Guideline Centre for patients presenting with STEMI.
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Base Case Analysis
The base case analysis directly compares the costs per procedure of transradial and transfemoral PCIs in England from 2010 to 2014 for each indication. To account for potential selection bias and confounding in the full BCIS data set, a 1-to-1 logistic regression propensity score-matched data set was generated. Matching was exact for procedure year and indication, and additional nonexact matching was performed to adjust for difference in age, sex, history of myocardial infarction, coronary artery bypass graft, PCI, stroke, hypertension, high cholesterol, peripheral vascular disease, valvular heart disease, diabetes mellitus, renal dysfunction, and cardiogenic shock. Missing values for patient history and comorbidities were imputed using the missing as absent heuristic. Operator-modifiable variables were not used to match. The propensity-matching algorithm uses optimal nearest neighbor matching, with samples chosen to minimize the average absolute different across all matched pairs.
Real-World Analysis
For the real-world analysis, the full BCIS data set on TRA and TFA PCI procedures for 2010 to 2014 was used to examine differences in procedure uptake and key cost drivers for transfemoral and transradial PCIs and the impact of recent trends in procedural access uptake over time for each English region. To analyze the effect of changes in procedural uptake over time in each region, the total hospital LoS, complications, and costs based on actual procedure uptake in each year from 2011 to 2014 were compared with those generated by applying the 2010 procedure uptake for each year. These results were then compared with those obtained by applying to each region the procedural uptake rate for the region with the highest TRA utilization to estimate the impact of more rapid TRA uptake. The baseline characteristics for the full BCIS data set used in this analysis are provided in the Table III in the Data Supplement.
The real-world analysis uses the full BCIS data set to allow for regional variation in LoS and complications and to estimate the actual economic impact of changes in TRA update that occurred from 2010 to 2014. However, patient characteristics may impact both on the choice to perform a TRA or TFA, as well as clinical outcomes, which may confound this analysis. Therefore, an additional analysis was performed using the propensity-matched data set used in the base case to assess the impact of potential bias in the unadjusted data set on the population-level results.
Sensitivity Analysis
Complications in the BCIS data are self-reported; it is, therefore, likely that the rates of complications are underestimated. A sensitivity analysis was consequently performed on the base case using complications rates from a published meta-analysis of randomized trials by Ferrante et al. 25 Pooled rates are available from this study for MACE, major bleeding, and vascular complications. For NSTEMI bleeding rates, the study by Ferrante et al 25 considered 3 studies: RIVAL, 10 Study of Access Site for Enhancement of PCI for Women, 26 and Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systematic Implementation of Angiox. 4 The RIVAL 10 study used a fairly conservative definition of major bleeding, whereas the SAFE-PCI study focused on a female-only population. 26 MATRIX used the Bleeding Academic Research Consortium criteria, 4 which are the current standard for defining bleeding events in clinical trials. Therefore, the current analysis uses data derived from the MATRIX trial. 4 The data used in the sensitivity analysis are available in Table IV in the Data Supplement.
The authors are unable to share data and study materials as this would not be allowed under the data sharing agreements with the National Institute of Cardiovascular Outcomes Research; however, analytic methods can be made available to other researchers for purposes of replicating the procedure.
RESULTS
Base Case Analysis
A total of 248 228 propensity-matched procedures between 2010 and 2014 were included in the base case analysis. The clinical and procedural characteristics stratified by access site are presented in Table 1 with clinical outcome data that the analysis was based on presented in Table 2 . An example flow diagram of the economic model calculations used in the base case analysis is provided in Figure I in the Data Supplement. Between 2010 and 2014, the total cost per procedure (access site/device, LoS, and complications) was £1120.84 for TFA (range, £997.99-1191.00) and £870.25 for TRA (range, £832.43-902.54), with TRA offering a cost saving of £250.59 (22% reduction; Table 3 ). The majority (76%) of the cost saving was attributable to LoS costs. The greatest cost saving was in the STEMI indication (£348.26), followed by NSTEMI/unstable (£282.21) and elective/stable (£153.88). In the sensitivity analysis on complication costs, a similar result was observed, with a cost saving of £251.84 (22%) per procedure for TRA versus TFA (Table 4) . Overall costs for TFA and TRA were both higher than the base case analysis because of the higher absolute complication rates in Ferrante et al 25 and the MATRIX 4 study relative to the BCIS data set.
Real-World Analysis
The percentage of PCI procedures performed by TRA has increased between 2010 and 2014 across all regions in England, but at varying rates, with rates between 20.7% and 79.8% reported in 2010 to 44.5 to 84.3% in 2014 ( Figure 1 ). Using these uptake rates, the actual uptake of TRA has resulted in a cost saving to the NHS of £13.31 million over 2010 to 2014, compared with the costs that would have been incurred if the percentage of TRA procedures had remained constant at the same level as in 2010 (Table 5) .
As shown in Figure 1 , the percentage uptake of TRA was much lower in some regions than others during 2010 to 2014. For example, TRA uptake in the South East Coast region increased from 20.7% in 2010 to 44.5% in 2014, compared with 79.8% and 84.3%, respectively, for the North East region. An analysis was, therefore, performed which assumed that all regions adopted TRA at the same rate as the region with highest utilization of TRA (North East). Increasing the rate of TRA uptake increased the total cost savings versus constant 2010 uptake rates to £33.40 million, a further increase of £20.09 million over and above the cost savings actually achieved during this period (Table 5) . A summary of the potential cost savings in each region versus those actually achieved over 2010 to 2014 is presented in Figure 2 , with a full breakdown provided in Table V in the Data Supplement.
In the analysis using the propensity-matched data set, total cost savings of £12.39 million were found to have been achieved during 2010 to 2014 based on actual TRA uptake, which increased to £30.85 million if uptake rates for all regions were assumed to match that of the region with the highest utilization (Table VI in 
DISCUSSION
This analysis is the first to consider the budget impact of TRA uptake from a national perspective in an unselected real-world cohort from a healthcare system that has transitioned to a predominantly TRA strategy. It is also the first study to examine the impact of the rate of adoption of TRA on national healthcare costs. Our current analysis has found that TRA is 24% less costly on a per-procedure basis in England, compared with TFA. On the basis of current adoption rates for TRA, cost savings of £13.31 million were estimated between 2010 and 2014 in the real-world analysis; however, if all regions had adopted TRA at the same rate as the region with the highest utilization (North East), a total national cost saving of £33.40 million could have been achieved during this period. The main component of these savings is the reduction in hospital stay; this not only results in a significant cost saving but will also increase the efficiency of the system by freeing up hospital beds for other patients. Finally, the greatest cost saving was found in the highest risk acute cases (STEMI cases), where the clinical benefit of TRA has been shown to be greatest. [2] [3] [4] [5] This real-world national economic data, therefore, adds to the already compelling clinical evidence supporting TRA for PCI. These findings should encourage decision makers to enhance adoption of TRA both for the benefit of patients and the healthcare economy. Although the current study is the first to consider the regional and national budget impact of TRA adoption, the cost per procedure for TRA versus TFA has been considered in 7 previous studies, 5 from a US perspective, 16 ,17,27-29 and 1 each from China 15 and Poland. 30 In line with the current analysis, these studies have consistently reported cost savings associated with TRA compared with TFA.
From a US perspective, 2 single-center studies by Muthusamy et al 27 and Roussanov et al 28 considered 2972 and 181 patients, respectively. Muthusamy et al 27 reported significant unadjusted procedural and postprocedural cost savings of $1019 and $957 for TRA versus TFA, respectively (P<0.05). After adjustment for patient characteristics, these savings remained significant for procedural costs, but not for postprocedural costs. 27 Roussanov et al 28 also reported significantly lower costs for TRA ($369.5±74.6) versus TFA with ($446.9±60.2) or without ($553.4±81.0) a closure device (P<0.001 for both). A multicenter national study of patients undergoing elective PCI from the NCDR data set by Amin et al 16 reported similar results (n=7121), with total cost savings of $830 (95% confidence interval [CI], $296-1364; P<0.001) for TRA versus TFA, which increased as the risk of bleeding increased. In a database analysis by Safley et al, 29 609 TRA patients were matched with 60 900 TFA patients. Total adjusted costs were significantly lower for TRA versus TFA by $553 (95% CI, $45-1060; P=0.033). Specifically, although dayof-procedure costs were similar between TRA and TFA, costs after this point through to postdischarge were lower for TRA. 29 A previous study undertaken in 5 US centers has suggested that cost benefit associated with TRA may relate to bleeding risk, with cost savings calculated in low risk: $642 (95% CI, $43-$1236; P=0.035); moderate risk: $706 (95% CI, $104-$1308; P=0.029); and high risk: $1621 (95% CI, $271-$2971; P=0.039). 31 Our analysis is in agreement with this, with the greatest saving observed in the higher bleeding risk STEMI population (£348.26) and the lowest gains achieved in the elective/stable group (£153.88), which is in line with our previous work that suggests that the greatest clinical benefit associated with TRA is in those patients at highest baseline bleeding risk. 2 In addition to these studies, a network meta-analysis by Safley et al 29 included 14 trials and a stochastic simulation model of per-case costs from a US perspective and reported a cost saving of $275 (95% CI, −$374 to −$183) per patient from the hospital perspective with TRA versus TFA.
From a non-US perspective, Jin et al 15 conducted a single-center study of 5306 patients in China which reported a lower total adjusted cost for TRA, compared with TFA (adjusted difference ¥8081 [$1283]). Similarly, Kołtowski et al 30 conducted an economic analysis of the OCEAN RACE single-center trial (Access for percutaneous coronary intervention in STEMI: radial vs. femoralprospective, randomized clinical trial) in Poland (n=103), which reported a lower cost of therapeutic success for TRA versus TFA (€3060 versus €3374, respectively) and lower costs related to absence from work. Although these studies have reported cost savings with TRA in comparison to TFA, only 1 study including 103 patients from Poland has considered a European perspective and none have used a national all-comer data set that does not exclude acute coronary syndrome (ACS) cases or other high-risk nonelective cases 16 where the clinical benefit derived from TRA is greatest. 2 Furthermore, none have considered the budget impact of TRA uptake at a regional or national level. The current analysis uses a robust and transparent economic model based on a large real-world data set. This data set includes the largest patient population modeled to date for TRA and is the first data set used where TRA has grown to be the most commonly used access site nationally.
As with all budget impact economic models, there are many limitations with the current analysis, with many cost assumptions made. Where possible, a conservative approach has been taken with estimates around costings and, therefore, is more likely to result in an underestimation of the cost benefits for the TRA versus TFA approach rather than an overestimation. First, differences in pharmacotherapy costs associated with each procedure were not considered because of a lack of available data. It is possible that clinicians using TRA may treat more aggressively with pharmacological therapy, because of a lower risk of bleeding compared with TFA, although drugs costs represent only a small component of total healthcare costs. Similarly, the number and types of stents used were not costed into the analysis as the cost of a stent will vary at the individual center level, and these data are not available in the BCIS data set. Nevertheless, it is unlikely that access site choice will influence stent choice or number of stents used per case. Finally, access site crossover is not captured in the BCIS data, but hence we used access site crossover rates that were obtained from the RIVAL study 10 for STEMI and NSTEMI/unstable patients. Crossover rates could not be identified for stable patients from the literature, hence pooled crossover rates for ACS patients from the RIVAL study were applied. This is likely to be an overestimate of actual cross over rates observed in stable patients clinically, leading to a more conservative cost estimate than would be the actual case in this group of patients.
Second, it is likely that the LoS for NSTEMI/unstable patients has not been fully captured in the BCIS data. This is because in the United Kingdom, patients with NSTEMI admitted to hospitals without PCI facili- ties are often transferred as day cases to a PCI center before being discharged back to the center of admission for continuation of care. The BCIS data only captures the LoS for patients in the PCI center which may lead to underestimation of total healthcare costs for both access sites, particularly for NSTEMI cases. Our LoS for NSTEMI cases was shorter than other international registries, for example, the median LoS from the US Acute Coronary Treatment Intervention Outcomes Network Registry-Get With The Guidelines report was 3 days (interquartile range, 2-5 days). 32 Nevertheless, patients admitted to non-PCI centers treated as treat- LoS indicates length of stay; NSTEMI, non-ST-segment-elevation myocardial infarction; STEMI, ST-segment-elevation myocardial infarction; TFA, transfemoral access; and TRA, transradial access.
and-return cases that sustain periprocedural complications will remain in the PCI center so would expect that differences related to LoS occurring as a consequence of vascular complications would still be captured in the data analyzed.
Third, because the data come from a national registry, the baseline characteristics of the patients by access site are different, with patients undergoing PCI through the transfemoral route older, with more comorbidity and tend to be more hemodynamically unstable as 4.0% of TFA patients were admitted with cardiogenic shock and 1.3% required an intra-aortic balloon pump compared with 2.9% and 1.3% rates, respectively, in the TRA cohort. This may have contributed to the greater complication rates and extended LoS in hospital observed in TFA patients particularly in the real-world analysis; however, we attempted to reduce differences between the cohorts in an analysis using the propensity-matched data set which found that the cost savings with TRA remained consistent. Nevertheless, there may still be residual confounding even in the propensity score-matched cohorts. For example, the femoral cohorts may be frailer and have a greater prevalence of adverse unmeasured characteristics that contribute to the increased LoS still observed after propensity score matching.
Similarly, the BCIS registry only provides operator identifiable information for 2013 onwards, so we were unable to assess the experience of operators in each region who are undertaking TRA, which could potentially impact on complications rates, crossover rates and subsequent costs.
Fourth, costs for MACE were not included in the analysis. MACE is a composite measure of several MACEs, and for this reason, it was not possible to identify an appropriate and accurate cost of MACE as a complication for patients who have undergone a PCI. However, as MACE complications are infrequent in general and are less frequent in patients who received TRA than TFA, 25 this is a conservative assumption which may underestimate the cost saving with TRA.
Furthermore, differences in the number and type of catheters between TRA and TFA were not considered. This approach is generally consistent with previous Calculated as the percentage of radial and femoral procedures. Some procedures were classified as multiple/other; when the access site was not clear or >1 site was used in the same procedure, these data were excluded from the analysis. 28 reported that fewer catheters were required, and catheter costs were lower, in the TRA group versus TFA. Kołtowski et al 30 did not consider catheter costs in isolation, but grouped these with other costs for single-use materials, and reported that costs for these materials were higher for TRA versus TFA. However, both studies concluded that TRA offered overall economic advantages over TFA. The exclusion of differences in number and type of catheters is, therefore, likely to have a minimal impact on the results of this study.
Mortality has not been included as a health economic outcome in this analysis. Mortality is often not included in such health economic analyze, as it does not incur a direct cost on the health service and is difficult to include in budget impact analyses. In addition, our previous analysis has already estimated the number of lives that may have potentially been saved in the United Kingdom because of an increased TRA uptake (450 between 2005 and 2012), and the number that could have been saved if TRA adoption were uniform nationally (264 over the same time period) using this data set. 11 Finally, gains may be clustered by hospital and our analysis, although it accurately provides information on overall costs gains, cannot explore potential heterogeneity. This is because of the great variability in TRA usage across centers, which would make withincenter matching inefficient. This might be particularly relevant in situations where there are institutional differences in hospital policies on LoS in nonelective cases, particularly between predominantly radial and femoral centers.
This analysis was conducted using UK data because of the availability of both clinical and cost data in the United Kingdom. However, the cost-saving findings should be generalizable to other countries, because of standardized clinical practice and similar financial considerations, even though the exact cost-saving [15] [16] [17] [27] [28] [29] [30] ; it is, therefore, highly likely that applying these cost savings to regional and national uptake rates for TRA would demonstrate that cost savings could potentially be achieved in these countries. Nevertheless, it must be borne in mind that the absolute savings calculated in this analysis may only be applicable to the United Kingdom, as other healthcare systems are financed and structured differently to that in the United Kingdom, and the case mix undertaken in countries at the earlier stages of their radial learning curve may be toward lower risk cases, where the magnitude of costs savings is less. Finally, it should be noted that TRA and TFA for stable patients are both typically performed as day case procedures in the United Kingdom; in countries which routinely have a longer hospital stay for the TFA procedure than for TFA, the cost savings are, therefore, likely to increase substantially.
CONCLUSIONS
This analysis of PCI performed in England demonstrates that the clinical advantages of TRA are accompanied with significant cost savings and shows that savings of £13.31 million have already been achieved during 2010 to 2014 based on current adoption rates. However, further cost savings can be achieved if adoption of TRA is increased, with a national cost saving of £33.40 million estimated if all regions in England adopted TRA at the same rate as the region with highest utilization. The results of the current study are highly relevant for payers, administrators, and policy-makers who face ever more constrained healthcare budgets, demonstrating that substantial cost savings can be achieved while improving clinical outcomes. The results of this study should, therefore, encourage a reduction in the variability in uptake between different English regions and between countries in Europe. 
